ACGL — Arch Capital Group Ltd.

The Q2 2026 print beat consensus on EPS and revenue, but the stock has pulled back over the past month as the primary Insurance segment's combined ratio worsened to 98.5% and underwriting income collapsed to $27M from $129M a year earlier. Sell-side is split: 16 Buy, 16 Hold, 2 Sell, with a consensus price target around $114. The combination of a decent headline quarter, a deteriorating P&C book, and a forward P/E of roughly 10.5x on 2026E EPS points to a sideways, watchful market.

Revenue grew from $3.3B in Q3 2023 to a peak of $5.4B in Q4 2025, but 2026 has inflected: FMP shows Q1 2026 revenue down about 5% YoY and Q2 2026 down about 10% YoY, while the research brief cites a higher $4.67B reported Q2 figure—some top-line definitional differences aside, the trend is clearly decelerating. Operating margins have been resilient: Q2 2026 was 27.3% versus 28.4% a year earlier, and EPS of $3.00 beat consensus despite the revenue drag. This looks like a cyclical top in primary P&C pricing rather than a structural collapse: Reinsurance ($410M underwriting income) and Mortgage ($220M) are offsetting a deteriorating primary insurance book.

The reported trailing P/E of 7.6x versus the 5-year average of 9.4x looks cheap, but that comparison is flattered by elevated 2025 earnings. On 2026E EPS of roughly $9.39, ACGL trades at about 10.5x forward earnings, which is above its own 5-year average P/E. P/B of 1.41x and P/S of 1.80x versus the 2.03x 5-year average are closer to fair value. The PEG ratio of 0.25 looks like a cyclical-earnings artifact and should not be read as a genuine growth signal. Net net: moderately priced, not the deep value the trailing P/E alone implies.

The price is effectively pricing in earnings normalization, not a rebound. If 2026 EPS lands near $9.40, the current price is roughly 10.5x forward earnings—reasonable but with no obvious margin of safety. A re-rating to 12x forward would imply about $113, while a miss on P&C margins could push the multiple toward 9x and the stock toward the high-$80s. The playbook is to wait for evidence that primary insurance margins are stabilizing before paying up.

As of 2026-08-27, RSI of 47.15 is neutral; the stock is 0.43% below its 20-day, 0.65% below its 50-day, and 3.0% above its 200-day moving average. That is a range-bound, consolidating pattern after a pullback from the $107.09 high—not a breakdown. There is no strong entry signal here; a decisive reclaim of the 50-day or a successful test of the 200-day would be the more informative markers.

• P&C pricing is softening in primary and E&S lines as competitive capacity returns, driving combined ratios higher.
• Catastrophe exposure remains a live risk; Q2 2026 cat losses alone cost 7.6 points on the loss ratio and $201M pre-tax.
• Moderating interest rates likely reduce reinvestment income on Arch's large fixed-income portfolio over time.
• Mortgage credit conditions remain strong despite high rates, supporting Arch's U.S. and Australia mortgage insurance results.
• Aggressive capital return—$1.2B of buybacks in Q2 plus a $2.0B notes offering—supports EPS but adds modest financial leverage.

• Q3 2026 earnings around October 26, 2026—hurricane-season losses and the Insurance combined ratio will be the critical test.
• KBW Insurance Conference on September 9, 2026, where management may offer mid-quarter commentary on pricing and wind-season positioning.
• Continued large-scale buybacks could offset underwriting weakness and support book value per share.
• Post-Q2 sell-side estimate revisions have ticked upward; further upward revisions could support the stock.

• Primary Insurance combined ratio continues to deteriorate from 98.5%; if it crosses 100% on non-cat underwriting, that signals structural margin compression, not just weather noise.
• An active Atlantic hurricane season could dent Q3/Q4 earnings and book value.
• Favorable prior-year reserve releases fade; ACGL's earnings quality historically depends partly on reserve development.
• Softening prices and excess capacity in surplus lines could persist longer than the market expects.
• Lower interest rates could reduce investment income and pressure the reinvestment yield on the portfolio.

ACGL is a genuinely high-quality insurer—18% ROE, roughly 1.4x book value, strong free cash flow, and a diversified Reinsurance/Mortgage engine—but the primary insurance segment is in the early stages of a down-cycle. At $98.76 the stock is closer to fairly valued on forward earnings than to a bargain; I would need either a lower entry price or evidence that Insurance margins are stabilizing before taking a constructive position. This is a hold/watch rather than a clear buy or sell.

Applied an 11.6x multiple to 2026E EPS of $9.39, justified as a quality-adjusted premium to ACGL's 9.4x five-year average P/E because of its 18% ROE, conservative balance sheet, and diversified earnings stream. Cross-check: 1.6x book value per share of roughly $68 also lands near $109.